Keywords: extended, rituxan, regimen, boosts, response, eight-week, using
Extended Rituxan regimen boosts response
Article | 26 May 1999
An extended, eight-week regimen using Genentech's Rituxan (rituximab)has been shown to improve response rates compared to the approved four-week ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
